Cargando…

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Previous small-size studies reported BRAF-mutated NSCLC patients have comparable sensitivity to immune checkpoint inhibitors (ICIs). However, how BRAF mutation affects the tumor immune microenvironment (TIME) is unknown. We performed Nanostring-panel RNA sequencing to evaluate TIME in 57 BRAF mutate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hui, Zhang, Yongchang, Xu, Yanjun, Huang, Zhiyu, Cheng, Guoping, Xie, Mingyin, Zhou, Zichao, Yu, Yangyang, Xi, Wenjing, Fan, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772302/ https://www.ncbi.nlm.nih.gov/pubmed/36543792 http://dx.doi.org/10.1038/s41419-022-05510-4

Ejemplares similares

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
por: Chen, Kaiyan, et al.
Publicado: (2020)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
por: Cen, Shuyi, et al.
Publicado: (2021)

Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
por: Wang, Zhe, et al.
Publicado: (2021)

Insight on BRAF(V600E) mutated colorectal cancer immune microenvironment
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Co-mutations in tumor immune microenvironment and immunotherapy
por: Ma, Ling, et al.
Publicado: (2021)

Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation
por: Rittberg, Rebekah, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Vascular Microenvironment, Tumor Immunity and Immunotherapy
por: Lamplugh, Zachary, et al.
Publicado: (2021)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer
por: Xia, Yuxiao, et al.
Publicado: (2022)

Data-driven analysis to identify prognostic immune-related biomarkers in BRAF mutated cutaneous melanoma microenvironment
por: Huang, Biao, et al.
Publicado: (2022)

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
por: Swofford, Brenen P., et al.
Publicado: (2017)

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
por: Xie, Mingying, et al.
Publicado: (2022)

Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12
por: Xu, Yanjun, et al.
Publicado: (2023)

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
por: Madeddu, Clelia, et al.
Publicado: (2022)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

The immune suppressive microenvironment affects efficacy of radio‐immunotherapy in brain metastasis
por: Niesel, Katja, et al.
Publicado: (2021)

Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
por: Luo, Zhong-Wei, et al.
Publicado: (2020)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
por: Li, Ming, et al.
Publicado: (2021)

BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis
por: Zeng, Kaixuan, et al.
Publicado: (2016)

Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
por: White, Michael G., et al.
Publicado: (2021)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy
por: Xu, Yanjun, et al.
Publicado: (2020)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy
por: Lin, Lili, et al.
Publicado: (2023)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy
por: Xie, Feng, et al.
Publicado: (2019)

Immunotherapy: Reshape the Tumor Immune Microenvironment
por: LV, Bingzhe, et al.
Publicado: (2022)

Identification of an Exosome-Related Signature for Predicting Prognosis, Immunotherapy Efficacy, and Tumor Microenvironment in Lung Adenocarcinoma
por: Lin, Tao, et al.
Publicado: (2022)

Editorial: The role of angiogenesis and immune response in tumor microenvironment of solid tumor
por: Guo, Zichao, et al.
Publicado: (2023)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

BRAF Mutations in Canine Cancers
por: Mochizuki, Hiroyuki, et al.
Publicado: (2015)

The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia
por: Choi, Jeong Uk, et al.
Publicado: (2021)

Epigenetic modification and BRAF gene mutation in thyroid carcinoma
por: Huang, Guo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vo53h6ehmq7nrgg8as0vqgijit